Incidence of <scp>GLP</scp>‐1 receptor agonist use by women of reproductive age attending general practices in Australia, 2011–2022: a retrospective open cohort study
The prescribing of GLP-1 receptor agonists for women of reproductive age is increasing in Australia, and most prescriptions are for women not diagnosed with type 2 diabetes. Fewer than one in four women are using contraception at the time of treatment initiation, and a considerable number are pregnant within six months of the initial prescribing of GLP-1 receptor agonists. Further evidence and guidelines are needed to support the safe and effective use of GLP-1 receptor agonists by women of reproductive age.
Authors
- Danielle Mazza (ORCID: https://orcid.org/0000-0001-6158-7376)
- Kailash Thapaliya (ORCID: https://orcid.org/0000-0002-2897-6844)
- Barbara Kirsten
- Arianne Sweeting (ORCID: https://orcid.org/0000-0001-6843-6247)
- Amanda J. Poprzeczny (ORCID: https://orcid.org/0000-0002-6162-0305)
- Luke E. Grzeskowiak (ORCID: https://orcid.org/0000-0001-8554-4696)
Institutions
- The University of Sydney (AU)
- Flinders University (AU)
- Royal Prince Alfred Hospital (AU)
- Women's and Children's Hospital (AU)
- SA Health (AU)
- South Australian Health and Medical Research Institute (AU)
- Sydney Local Health District (AU)
- Monash University (AU)
- The University of Adelaide (AU)
Publication Details
- Journal
- The Medical Journal of Australia
- Published
- 2025-09-01
- DOI
- https://doi.org/10.5694/mja2.70026
- Citations
- 6
- Primary Topic
- Gestational Diabetes Research and Management
- Type
- article
- Field-Weighted Citation Impact
- 12.34
Funders
- Channel 7 Children's Research Foundation
- Flinders University
- Medical Research Council
- National Health and Medical Research Council